|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2001-10-10
|
|
pubmed:abstractText |
To determine the effect of tumor necrosis factor alpha (TNFalpha) blockade with etanercept on the clinical manifestations of resistant spondylarthropathy (SpA) and on axial and peripheral entheseal lesions using magnetic resonance imaging (MRI).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2112-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11592375-Adult,
pubmed-meshheading:11592375-Antirheumatic Agents,
pubmed-meshheading:11592375-Female,
pubmed-meshheading:11592375-Finger Joint,
pubmed-meshheading:11592375-Humans,
pubmed-meshheading:11592375-Immunoglobulin G,
pubmed-meshheading:11592375-Lumbar Vertebrae,
pubmed-meshheading:11592375-Magnetic Resonance Imaging,
pubmed-meshheading:11592375-Male,
pubmed-meshheading:11592375-Middle Aged,
pubmed-meshheading:11592375-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:11592375-Sacroiliac Joint,
pubmed-meshheading:11592375-Severity of Illness Index,
pubmed-meshheading:11592375-Spondylitis, Ankylosing,
pubmed-meshheading:11592375-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study.
|
|
pubmed:affiliation |
The University of Leeds, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
